TLSI TriSalus Life Sciences, Inc. Insider Trading

Director Wahlstrom buys 60,000 TLSI shares at $2.53; holdings up 68.5% to 147.6K, stock -61.9% from 52-week high, but 3 prior same-ticker buys showed 100% well-timed at 90-day horizon.

Wahlstrom Mats, a director of TriSalus Life Sciences, purchased 60,000 shares at $2.53 on 2026-05-15 (total value $151,800.00), expanding his holdings by 68.5% to 147.6K shares. This purchase arrives after a sharp equity price decline: the stock is -61.9% from its 52-week high of $7.95 and down -34.8% in the past 30 days. The timing signal, however, appears instructive: across his 3 prior open-market transactions at TLSI (November 2024), Wahlstrom's buys exhibited a 100% well-timed rate at the 90-day horizon, with subsequent returns ranging from +25.7% to +36.8%, despite negative 30-day returns (-2.6% to -11.0%) on those same trades. This pattern suggests Wahlstrom has historically purchased when TLSI shares were depressed in the near term yet recovered materially within 90 days. Underlying fundamentals show the company posted $8.9M revenue and $1.5M net income last quarter, with +53.4% annual revenue growth, though it remains unprofitable on a full-year basis. Investors should monitor whether this 60,000-share accumulation follows the same rebound trajectory Wahlstrom's prior three purchases at this ticker have exhibited.

Director Stansky buys 610,000 shares at $2.50 for $1,525,000 at TLSI; stock down -61.9% from 52-week high, 2 prior buys at this ticker showed 0% 90-day win rate.

Director Michael P Stansky purchased 610,000 shares across 2 separate transactions on 2026-05-15 at $2.50 per share for a total of $1,525,000.00, increasing his post-transaction holdings to 399,698 shares. The purchase price of $2.50 sits well below the current price of $3.03 and dramatically below the 52-week high of $7.95, with the stock currently -61.9% from its peak and down -34.8% over 30 days. Critically, Stansky's same-ticker history at TLSI shows 2 prior buys on 2026-02-23, both yielding -34.6% average 90-day returns with a 0% win rate at the 90-day mark—a pattern of unsuccessful timing on this specific stock that provides context for evaluating this latest accumulation despite the company's recent positive fundamentals (53.4% annual revenue growth, $1.5M net income latest quarter).

CFO Patience David buys 7,100 shares of TLSI at $2.43; stock down -34.8% in 30 days as cluster buy emerges.

Patience David, CFO of TriSalus Life Sciences, purchased 7,100 shares at $2.43 on 2026-05-15, increasing holdings to 275,757 shares. The timing is notable: the stock has declined -34.8% over the past 30 days and -36.5% over 90 days, trading at $3.03 (down -61.9% from its 52-week high of $7.95). His prior open-market buy at this ticker on 2026-02-23 resulted in a -34.6% 90-day return, and his cross-ticker track record shows zero wins from one prior buy (avg 90d return -34.6%). The transaction occurs amid a cluster pattern: 3 other insiders also bought within the past 14 days. While the company shows strong fundamentals—annual revenue growth of +53.4%, latest quarterly revenue of $8,899,000.00, and net income of $1,539,000.00—it was unprofitable over its most recent full fiscal year, creating a mixed signal between growth trajectory and profitability.

Director Gordon Gary B. buys 10,000 shares of TLSI at $2.46; stock down -61.9% from 52-week high, cluster of 4 other insider buys in past 14 days.

Director Gordon Gary B. purchased 10,000 shares at $2.46 on 2026-05-15, increasing his holdings to 72.5K shares (+16.0% vs pre-transaction holdings). The purchase occurs as the stock trades at $3.03, down -61.9% from its 52-week high of $7.95 and -34.8% over the past 30 days. His prior buy at TLSI on 2026-02-23 showed a 90d return of -34.6%, and across his cross-ticker track record, his 1 prior buy produced an avg 90d return of -34.6% with a 0.00% win rate, indicating a pattern of unfavorable post-purchase price performance. The filing also shows that 4 other insiders bought within the past 14 days, forming a cluster pattern. Against this backdrop, the company reported quarterly revenue of $8.9M and net income of $1.5M, with annual revenue growth of +53.4%, though full-year results were unprofitable and market cap stands at $186.1M.

CEO Szela buys 30,487 shares at $4.10; stock down 33.5% from 52-week high, as company unprofitable with -$10.8M net income.

CEO Mary T Szela purchased 30,487 shares at $4.10, increasing her holdings to 773,289 shares, concurrent with a multi-insider buying cluster (4 other insiders bought within 14 days). The purchase occurs as TLSI stock has declined 33.5% from its 52-week high and dropped 20.7% over the past 90 days, while the company reported negative net income of -$10.8M on latest quarterly revenue of $11.6M despite 59.0% annual revenue growth. Her same-ticker trade history shows mixed predictive value: three of five prior TLSI purchases achieved positive 90-day returns, though the most recent prior buy on 2025-01-30 followed a pattern where gains materialized at the 30-day mark but reversed by 90 days. The synchronized multi-insider accumulation during a drawdown, coupled with the company's unprofitability, warrants examination of whether this reflects conviction in the business turnaround or a response to valuation dislocations in a loss-making firm.

Director Gordon Gary B. buys 9,756 shares at $4.10; stock down 20.7% in 90 days amid cluster buy by 4 other insiders

Director Gordon Gary B. established an initial 9,756-share position in TriSalus Life Sciences at $4.10 on 2026-02-23, investing $39,999.60 total. This purchase occurs within a 14-day window in which 4 other insiders also bought shares, forming a coordinated cluster-buy pattern. The company is generating revenue growth of +59.0% year-over-year but remains unprofitable with a full-year net income of $-10,811,000.00 and quarterly net income of $-10,811,000.00. The timing of this buy follows a significant stock decline: the current price of $4.99 is -33.5% from the 52-week high of $7.50 and -20.7% lower than 90 days ago. The convergence of multiple insider purchases alongside deteriorated valuation metrics warrants scrutiny of whether insiders view the depressed price as a buying opportunity relative to underlying fundamentals.

Director Valle William buys 30.5K shares of TLSI at $4.10; stock down -33.5% from 52-week high, net income negative; cluster of 4 other insiders bought within 14 days.

Valle William, a director, purchased 30,487 shares at $4.10 on 2026-02-23, establishing an initial position of 30.5K shares. This transaction occurs within a 14-day window where 4 other insiders also bought TLSI stock, forming a cluster buy pattern. The company's recent fundamentals are mixed: annual revenue growth of +59.0% is offset by a negative net income of $-10.8M in the latest quarter and a full-year loss, while the stock has declined -33.5% from its 52-week high of $7.50 and -8.3% over the past 30 days. The simultaneous buying activity by multiple insiders suggests coordinated interest in the stock at depressed price levels, though the company's continued unprofitability and recent downward momentum are relevant context for evaluating the signal.

CFO Patience David bought 3,657 shares of TLSI at $4.10; cluster of 4 other insider buys in past 14 days amid -33.5% 52-week drawdown

Patience David, CFO of TriSalus Life Sciences, purchased 3,657 shares at $4.10 on 2026-02-23, increasing her holdings from 265.0K to 268.7K shares. This transaction is part of a broader cluster: 4 other insiders also bought within the past 14 days, suggesting coordinated confidence despite deteriorating market conditions. The stock trades at $4.99 today, down -33.5% from its 52-week high of $7.50 and down -8.3% over 30 days, indicating the company is in a significant drawdown. While the company posted +59.0% annual revenue growth, it remains deeply unprofitable with a -$10.8M net loss in the latest quarter against $11.6M in quarterly revenue, highlighting a critical profitability gap. The cluster buy pattern during a sharp price decline warrants examination of whether insiders are accumulating at depressed levels or responding to operational headwinds.

Director Stansky buys 361,098 shares for $1.5M at $4.10 amid cluster buy; TLSI unprofitable but +59% revenue growth.

Director Michael P. Stansky purchased 361,098 shares across 2 separate transactions totaling $1,480,501.80 at $4.10 per share on 2026-02-23. This transaction occurs within a cluster pattern where 4 other insiders also bought within the past 14 days, suggesting coordinated insider accumulation despite the company's challenging profitability position. TriSalus is unprofitable with net income of $-10,811,000.00 over its most recent full fiscal year, yet the company generated $11,566,000.00 in latest-quarter revenue with +59.0% annual revenue growth, indicating aggressive commercial traction in a pre-profitability stage. The stock trades at $4.99 (current), down 33.5% from its 52-week high of $7.50 and down 20.7% over 90 days, placing the insider purchases at a lower valuation than historical recent levels.

CFO James Young buys 6,000 shares of TLSI at $5.65; cluster of 2 other insiders bought within 14 days

CFO James Young purchased 6,000 shares (6.0K shares) of TriSalus Life Sciences at $5.65 on 2025-02-05, increasing his holdings from 24,000 shares to 30,000 shares (+25.0% vs pre-transaction holdings). This buy occurs within a cluster pattern—2 other insiders also purchased shares within the past 14 days—suggesting coordinated appetite from the insider team. The company reported revenue of $7,349,000.00 (latest quarter) with annual revenue growth of +49.3%, though it remains unprofitable with net income of $-2,399,000.00 for its most recent full fiscal year. The stock currently trades at $5.38, down -47.5% from its 52-week high of $10.25 but up +27.2% over the past 90 days, indicating recent recovery from earlier lows. The cluster buy pattern suggests management sees value at current levels despite the company's ongoing losses.